Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors

Clinical trial NCT06727617 · RECRUITING

Trial details

NCT number: NCT06727617
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cervical Cancers

Start date: 2024-11-19
Primary completion: 2025-12-31
Enrollment: 134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.